Double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of maintenance therapy with anti-TA-MUC1 monoclonal antibody PankoMab after chemotherapy in patients with recurrent epithelial ovarian carcinoma.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS5622-TPS5622
Author(s):  
Jonathan A. Ledermann ◽  
Ingo von Broen ◽  
Frank Zimmermann ◽  
Johannes Nippgen ◽  
Steffen Goletz
2004 ◽  
Vol 43 (5) ◽  
pp. A254
Author(s):  
Ralph M Vicari ◽  
Bernard Chaitman ◽  
Deborah Keefe ◽  
William B Smith ◽  
Steven G Chrysant ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document